复方菥蓂治疗甲胎蛋白阳性肝病54例初步观察

Treatment of 54 Patients with a-fetoprotein Positive Liver Diseases by Thaspi Arvense L. Compound

采用复方菥蓂治疗54例甲胎蛋白(AFP)阳性肝病患者。对 AFP 阳性原发性肝癌,AFP 下降率为71.34％,明显高于对照组的22.22％(P<0.01);半年以上生存率为66.67％,明显高于对照组的27.78％(P<0.01);对 AFP 低持阳肝病,AFP 阴转率为93.94％,明显高于对照组的66.67％(P<0.05);随访1～3年,肝癌发生率为3.03％,明显低于对照组的22.22％(P<0.05)。初步认为,本方是阻遏 AFP 阳性的有效药物。

54 patients with α-fetoprotein (AFP)positive Uver diseases were treated by Thaspi arvense L. compound (TALC). The results showed that of the patients with AFP positive primary carcinoma of Uver,the descending rate of AFP in TALC group was 71. 34%, but 22. 22% in the control(P<0. 01)and the survival rate of more than 6 months in TALC group was 66. 67% but 27. 78% in the control (P<0. 01) ; of the patients with persistent low level AFP positive liver diseases, the negative rate of AFP in TALC group was 93. 94%, but 66. 67% in the control (P<0. 05)and the incidence rate of liver cancer in TALC group was 3. 3%, but 22. 22% in the control after a follow-up of 1-3 year. These results suggest that TALC is effective in the treatment of AFP positive patient.